Literature DB >> 17038273

Goals and guidelines for treating hypertension in a patient with heart failure.

Douglas S Lee1, Ramachandran S Vasan.   

Abstract

Hypertension promotes left ventricular (LV) hypertrophy and myocardial remodeling and is frequently present in patients with systolic or diastolic heart failure. Control of hypertension in both of these settings may attenuate progressive LV hypertrophy and remodeling and improve clinical outcomes. Guidelines for the management of heart failure recommend that hypertension should be treated in all patients with preclinical heart failure as well as in those with heart failure with reduced or preserved LV systolic function. Consistent with national hypertension guidelines, the goal for blood pressure control in hypertensive patients with heart failure is less than 140/90 mm Hg, but lower targets (< 130/80 mm Hg) may be desirable in those with concomitant diabetes mellitus or renal disease. Angiotensin-converting enzyme inhibitors, angiotensin II receptor antagonists, and beta-adrenoreceptor antagonists are first-line options for hypertension treatment in heart failure. Calcium channel antagonists and the alpha blocker doxazosin should be avoided. Episodes of recurrent pulmonary edema and hypertension may also indicate underlying severe renovascular disease that may respond to percutaneous renal artery intervention.

Entities:  

Year:  2006        PMID: 17038273     DOI: 10.1007/s11936-006-0054-2

Source DB:  PubMed          Journal:  Curr Treat Options Cardiovasc Med        ISSN: 1092-8464


  39 in total

Review 1.  Diabetes mellitus and congestive heart failure. Further knowledge needed.

Authors:  L Soläng; K Malmberg; L Rydén
Journal:  Eur Heart J       Date:  1999-06       Impact factor: 29.983

2.  Diastolic heart failure in the community: clinical profile, natural history, therapy, and impact of proposed diagnostic criteria.

Authors:  Horng H Chen; John G Lainchbury; Michele Senni; Kent R Bailey; Margaret M Redfield
Journal:  J Card Fail       Date:  2002-10       Impact factor: 5.712

Review 3.  Percutaneous intervention for renovascular disease: rationale and patient selection.

Authors:  Dharsh Fernando; Joseph Garasic
Journal:  Curr Opin Cardiol       Date:  2004-11       Impact factor: 2.161

4.  Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.

Authors:  Bertram Pitt; Willem Remme; Faiez Zannad; James Neaton; Felipe Martinez; Barbara Roniker; Richard Bittman; Steve Hurley; Jay Kleiman; Marjorie Gatlin
Journal:  N Engl J Med       Date:  2003-03-31       Impact factor: 91.245

5.  A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group.

Authors:  A S Levey; J P Bosch; J B Lewis; T Greene; N Rogers; D Roth
Journal:  Ann Intern Med       Date:  1999-03-16       Impact factor: 25.391

6.  Clinical benefit of renal artery angioplasty with stenting for the control of recurrent and refractory congestive heart failure.

Authors:  Bruce H Gray; Jeffrey W Olin; Mary Beth Childs; Timothy M Sullivan; J Michael Bacharach
Journal:  Vasc Med       Date:  2002       Impact factor: 3.239

7.  Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure.

Authors:  Aram V Chobanian; George L Bakris; Henry R Black; William C Cushman; Lee A Green; Joseph L Izzo; Daniel W Jones; Barry J Materson; Suzanne Oparil; Jackson T Wright; Edward J Roccella
Journal:  Hypertension       Date:  2003-12-01       Impact factor: 10.190

8.  Effect of aldosterone antagonism on myocardial dysfunction in hypertensive patients with diastolic heart failure.

Authors:  Philip M Mottram; Brian Haluska; Rodel Leano; Diane Cowley; Michael Stowasser; Thomas H Marwick
Journal:  Circulation       Date:  2004-07-26       Impact factor: 29.690

9.  Comparative effects of irbesartan versus amlodipine on left ventricular mass index in hypertensive patients with left ventricular hypertrophy.

Authors:  Carlo Gaudio; Fabio Massimo Ferri; Marco Giovannini; Giuseppe Pannarale; Paolo Emilio Puddu; Alessandro Vittore; Maria Stella Fera; Carmine Dario Vizza; Francesco Fedele
Journal:  J Cardiovasc Pharmacol       Date:  2003-11       Impact factor: 3.105

10.  Renal function as a predictor of outcome in a broad spectrum of patients with heart failure.

Authors:  Hans L Hillege; Dorothea Nitsch; Marc A Pfeffer; Karl Swedberg; John J V McMurray; Salim Yusuf; Christopher B Granger; Eric L Michelson; Jan Ostergren; Jan Hein Cornel; Dick de Zeeuw; Stuart Pocock; Dirk J van Veldhuisen
Journal:  Circulation       Date:  2006-02-07       Impact factor: 29.690

View more
  1 in total

1.  Difficulties in achieving arterial hypertension control.

Authors:  Genel Sur; Maria Sur; Liana Kudor-Szabadi; Lucia Sur
Journal:  Maedica (Buchar)       Date:  2011-04
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.